FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to a formulation for oral delayed and controlled delivery of activated charcoal to the lower part of the intestine of mammals, as well as the use of this formulation to reduce flatulence, unpleasant stool odor, bad breath or food intolerance in domestic or farm animals. Said formulation contains a core containing activated charcoal mixed with carrageenan, in which the amount of carrageenan is 5–25 wt.% by weight of the composition and the amount of activated charcoal is 60–95 wt.% by weight of the composition, and an outer coating layer.
EFFECT: implementation of the invention allows to obtain a composition that delivers a large amount of activated charcoal in the lower part of the intestine to ensure the best adsorption.
19 cl, 19 dwg, 9 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION WITH CONTROLLED RELEASE | 2003 |
|
RU2336865C2 |
| CHOLESTYRAMINE PELLETS AND THEIR PRODUCTION METHODS | 2017 |
|
RU2775800C2 |
| ORAL CHOLESTYRAMINE COMPOSITION AND APPLICATION THEREOF | 2017 |
|
RU2750944C2 |
| SOLID COMPOSITIONS CONTAINING 5-AMINOLEVULINIC ACID | 2010 |
|
RU2527328C2 |
| DRUG FORM FOR DELIVERY OF MEDICATION INTO LARGE INTESTINE | 2007 |
|
RU2478372C2 |
| CHOLESTYRAMINE PELLETS, ORAL CHOLESTYRAMINE COMPOSITIONS AND THEIR USE | 2018 |
|
RU2782016C2 |
| PHARMACEUTICAL FORM FOR DRUG DELIVERY TO THE COLON | 2007 |
|
RU2646825C2 |
| PERORAL PHARMACEUTICAL COMPOSITIONS OF MESALAZINE | 2017 |
|
RU2744576C2 |
| ORAL PHARMACEUTICAL COMPOSITIONS OF NICOTINAMIDE | 2017 |
|
RU2738114C2 |
| PHARMACEUTICAL MEDICINAL FORM, RESISTANT TO GASTRIC JUICE ACTIVITY, WHICH INCLUDES N-(2-(2-PHTHALIMIDOETOXY)ACETYL)-L-ALANYL-D-GLUTAMIC ACID (LK 423) | 2005 |
|
RU2375047C2 |
